Cargando…

Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy

BACKGROUND: Hyperprogressive disease (HPD) is a new progressive pattern in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to investigate risk factors associated with HPD in advanced HCC patients undergoing anti-PD-1 therapy. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lu, Wu, Lingeng, Chen, Qiuying, Zhang, Bin, Liu, Jing, Liu, Shuyi, Mo, Xiaokai, Li, Minmin, Chen, Zhuozhi, Chen, Luyan, You, Jingjing, Jin, Zhe, Chen, Xudong, Zhou, Zejian, Zhang, Shuixing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846667/ https://www.ncbi.nlm.nih.gov/pubmed/33554079 http://dx.doi.org/10.1016/j.eclinm.2020.100673

Ejemplares similares

Three-Dimensional CT for Quantification of Longitudinal Lung and Pneumonia Variations in COVID-19 Patients
por: Chen, Qiuying, et al.
Publicado: (2021)

MRI texture-based machine learning models for the evaluation of renal function on different segmentations: a proof-of-concept study
por: Mo, Xiaokai, et al.
Publicado: (2023)

Novel coronavirus disease 2019 (COVID-19): relationship between chest CT scores and laboratory parameters
por: Zhang, Bin, et al.
Publicado: (2020)

Clinical Utility of a Nomogram for Predicting 30-Days Poor Outcome in Hospitalized Patients With COVID-19: Multicenter External Validation and Decision Curve Analysis
por: Zhang, Bin, et al.
Publicado: (2020)

Real-time automatic prediction of treatment response to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma using deep learning based on digital subtraction angiography videos
por: Zhang, Lu, et al.
Publicado: (2022)

CT-based radiomics for predicting the rapid progression of coronavirus disease 2019 (COVID-19) pneumonia lesions
por: Zhang, Bin, et al.
Publicado: (2021)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis
por: Jin, Zhe, et al.
Publicado: (2020)

Predicting Intensive Care Unit Length of Stay After Acute Type A Aortic Dissection Surgery Using Machine Learning
por: Chen, Qiuying, et al.
Publicado: (2021)

Elevated fasting blood glucose at admission is associated with poor outcomes in patients with COVID-19
por: Liu, Shuyi, et al.
Publicado: (2021)

Radiomic Nomogram Improves Preoperative T Category Accuracy in Locally Advanced Laryngeal Carcinoma
por: Wang, Fei, et al.
Publicado: (2019)

Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Zhang, Bin, et al.
Publicado: (2020)

Intra-arterial chemotherapy as primary or secondary treatment for infants diagnosed with advanced retinoblastoma before 3 months of age
por: Chen, Qiuying, et al.
Publicado: (2019)

Association of MRI-derived radiomic biomarker with disease-free survival in patients with early-stage cervical cancer
por: Fang, Jin, et al.
Publicado: (2020)

Comparison of Clinical Features and CT Temporal Changes Between Familial Clusters and Non-familial Patients With COVID-19 Pneumonia
por: Liu, Shuyi, et al.
Publicado: (2021)

Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis
por: Chen, Qiuying, et al.
Publicado: (2018)

Machine learning classifiers for predicting 3-year progression-free survival and overall survival in patients with gliomas after surgery
por: Zhang, Bin, et al.
Publicado: (2021)

Machine-learning based MRI radiomics models for early detection of radiation-induced brain injury in nasopharyngeal carcinoma
por: Zhang, Bin, et al.
Publicado: (2020)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
por: Mao, Shiyu, et al.
Publicado: (2019)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report
por: Yang, Hong-Yu, et al.
Publicado: (2023)

Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients
por: Yan, Jing, et al.
Publicado: (2021)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

The potential indicators for pulmonary fibrosis in survivors of severe COVID-19
por: Huang, Wenhui, et al.
Publicado: (2021)

The potential and challenges of radiomics in uncovering prognostic and molecular differences in interstitial lung disease associated with systemic sclerosis
por: Zhang, Lu, et al.
Publicado: (2022)

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer
por: Chen, Shiyun, et al.
Publicado: (2021)

Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
por: Gong, Caifeng, et al.
Publicado: (2023)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
por: Chen, Shiyun, et al.
Publicado: (2023)

Anormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge
por: You, Jingjing, et al.
Publicado: (2020)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature
por: Singh, Balraj, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_514vdl9e2uc4r1gap5jp2j0t1p